[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336127-105":59,"doc-detail-336127-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","measures-of-longitudinal-immune-dysfunction-and-risk-of-aids-and-non-aids-defining-malignancies-in-antiretroviral-treated-people-with-human-immunodeficiency-virus-major-article-risk-and-prognostic-analysis","Measures of Longitudinal Immune Dysfunction and Risk of AIDS and Non-AIDS Defining Malignancies in Antiretroviral-Treated People With Human Immunodeficiency Virus - Major Article - risk and prognostic analysis","","Human immunodeficiency virus (HIV) infection drives chronic immune activation and inflammation that can persist even when viral suppression is achieved on fully active antiretroviral therapy (ART), increasing cancer risk. The prognostic value of low CD4:CD8 ratio and elevated CD8 counts for malignancy risk in this setting remains uncertain. Cox proportional hazards models assessed how baseline CD4:CD8 ratio relates to AIDS-defining and non-AIDS-defining malignancies while adjusting for confounders and cumulative, time-varying exposures.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/measures-of-longitudinal-immune-dysfunction-and-risk-of-aids-and-non-aids-defining-malignancies-in-antiretroviral-treated-people-with-human-immunodeficiency-virus-major-article-risk-and-prognostic-analysis/336127/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/measures-of-longitudinal-immune-dysfunction-and-risk-of-aids-and-non-aids-defining-malignancies-in-antiretroviral-treated-people-with-human-immunodeficiency-virus-major-article-risk-and-prognostic-analysis/336127.png","ImageObject",300,407,{"name":92,"@type":93},"Olivia Brown","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What immune marker was evaluated for cancer risk in ART-treated people with HIV?","Question",{"text":113,"@type":114},"The study evaluated the CD4:CD8 ratio and its association with the hazard of AIDS-defining malignancy (ADM) and non-AIDS-defining malignancy (NADM).","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were time-dependent effects handled in the analysis?",{"text":118,"@type":114},"Cox proportional hazard models adjusted for known confounders and included time-dependent cumulative and lagged exposures of the CD4:CD8 ratio to account for evolving risk and reduce reverse causality.",{"name":120,"@type":111,"acceptedAnswer":121},"What did low CD4:CD8 ratio indicate about future malignancy risk?",{"text":122,"@type":114},"CD4:CD8 ratios below 0.5 (vs above 1.0) were independently associated with a higher 12-month time-lagged risk of ADM and infection-related malignancies.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},336127,1790193363,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Clinical Infectious Diseases  \nMAJOR ARTICLE  \nMeasures of Longitudinal Immune Dysfunction and Risk of AIDS and Non-AIDS Defining Malignancies in Antiretroviral-Treated People With Human Immunodeficiency Virus  \nFrédérique Chammartin,1, Amanda Mocroft,2,3 Alexander Egle,4 Robert Zangerle,5 Colette Smith,6 Cristina Mussini,7 Ferdinand Wit,8  \nJörg Janne Vehreschild,9 Antonella d’Arminio Monforte,10 Antonella Castagna,11 Laurent Bailly,12 Johannes Bogner,13 Stéphane de Wit,14 Raimonda Matulionyte,15 Matthew Law,16 Veronica Svedhem,17 Joan Tallada,18 Harmony P Garges,19 Andrea Marongiu,20 Álvaro H. Borges,2,21 Nadine Jaschinski,2 Bastian Neesgaard,2 Lene Ryom,2,22 and Heiner C Bucher1; for the RESPOND Study Group  \n1Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland; 2CHIP, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; 3Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, United Kingdom; 4Austrian HIV Cohort Study (AHIVCOS), Paracelsus Medical University Hospital, Salzburg, Austria; 5Austrian HIV Cohort Study (AHIVCOS), Medizinische Universität Innsbruck, Innsbruck, Austria; 6The Royal Free HIV Cohort Study, Royal Free Hospital, University College London, London, United Kingdom; 7Modena HIV Cohort, Università degli Studi di Modena, Modena, Italy; 8AIDS Therapy Evaluation in the Netherlands (ATHENA) Cohort, HIV Monitoring Foundation, Amsterdam, The Netherlands; 9Department I of internal Medicine, University Hospital Cologne, Cologne, Germany; 10Italian Cohort Naive Antiretrovirals (ICONA), ASST Santi Paolo e Carlo, Milano, Italy; 11San Raffaele Scientific Institute, Università Vita-Salute San Raffaele, Milano, Italy; 12Nice HIV Cohort, Department of Public Health, Université Côte d’Azur—Centre Hospitalier Universitaire de Nice, UR2CA, Nice, France; 13Division of Infectious Diseases, Medizinische Klinik und Poliklinik IV, LMU University Hospital, LMU Munich, Munich, Germany; 14CHU Saint-Pierre, Centre de Recherche en Maladies Infectieuses a.s. b. l. , Brussels, Belgium; 15Vilnius University, Faculty of Medicine, Department of Infectious Diseases and Dermatovenerology; Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania; 16The Australian HIV Observational Database (AHOD), Kirby Institute, University of New South Wales, New South Wales, Australia; 17Division of Infectious Diseases, Department of Medicine, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden; 18European AIDS Treatment Group (EATG), Brussels, Belgium; 19ViiV Healthcare, Durham, North Carolina, USA; 20Gilead Sciences, Foster City, California, USA; 21Department of Infectious Diseases Immunology, Statens Serum Institut, Copenhagen, Denmark; and 22Department of Infectious Diseases 144, Hvidovre University Hospital, Copenhagen, Denmark  \nBackground. Human immunodeficiency virus (HIV) infection leads to chronic immune activation/inflammation that can persist in virally suppressed persons on fully active antiretroviral therapy (ART) and increase risk of malignancies. The prognostic role of low CD4:CD8 ratio and elevated CD8 cell counts on the risk of cancer remains unclear.  \nMethods. We investigated the association of CD4:CD8 ratio on the hazard of non-AIDS defining malignancy (NADM), AIDSdefining malignancy (ADM) and most frequent group of cancers in ART-treated people with HIV (PWH) with a CD4 and CD8 cell counts and viral load measurements at baseline. We developed Cox proportional hazard models with adjustment for known confounders of cancer risk and time-dependent cumulative and lagged exposures of CD4:CD8 ratio to account for timeevolving risk factors and avoid reverse causality.  \nResults. CD4:CD8 ratios below 0.5, compared to above 1.0, were independently associated with a 12-month time-lagged higher risk of","cbCaitVaqNqfaBjl","https://ap.wps.com/l/cbCaitVaqNqfaBjl","pdf",597197,"English","# Background\n# Methods\n## Time-varying exposure modeling\n# Results\n## CD4:CD8 ratio associations\n## Risk factors for NADMs and ADMs\n# Conclusions","[{\"question\":\"What immune marker was evaluated for cancer risk in ART-treated people with HIV?\",\"answer\":\"The study evaluated the CD4:CD8 ratio and its association with the hazard of AIDS-defining malignancy (ADM) and non-AIDS-defining malignancy (NADM).\"},{\"question\":\"How were time-dependent effects handled in the analysis?\",\"answer\":\"Cox proportional hazard models adjusted for known confounders and included time-dependent cumulative and lagged exposures of the CD4:CD8 ratio to account for evolving risk and reduce reverse causality.\"},{\"question\":\"What did low CD4:CD8 ratio indicate about future malignancy risk?\",\"answer\":\"CD4:CD8 ratios below 0.5 (vs above 1.0) were independently associated with a higher 12-month time-lagged risk of ADM and infection-related malignancies.\"}]","Measures of Longitudinal Immune Dysfunction and Risk of AIDS and Non-AIDS Defining Malignancies in Antiretroviral-Treated People With Human Immunodeficiency Virus - Major Article - risk and prognostic analysis | PDF",1790013700,25]